OncoMatch/Clinical Trials/NCT06978699
A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Is NCT06978699 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies XH-S003 Capsule for pnh - paroxysmal nocturnal hemoglobinuria.
Treatment: XH-S003 Capsule — This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Cannot have received: complement inhibitor
Patients who have not previously received any complement inhibitor therapy
Lab requirements
Blood counts
reticulocyte count <100×10^9/l, platelet count <30×10^9/l, or neutrophil count <0.5×10^9/l [excluded]
Liver function
alt, ggt, or alp >3×uln at screening [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06978699 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior complement inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify